FDA advisers have overwhelmingly rejected the agency's plan for reducing the inappropriate prescribing, misuse and abuse of extended-release opioids. During a July 22-23 joint meeting of the FDA's Anesthetic and Life Support Drugs and Drug Safety and Risk Management advisory committees, committee members voted 25-10 against a proposed Risk Evaluation and Mitigation Strategy, or REMS, for extended-release and long-acting opioid analgesics after deeming the plan insufficient to stop abuse of the painkillers.
Creating memories for families by sharing information relating to children and parents with regard to activities, products, school, home and more.
Advisory Committees Reject FDA Plan for Controlling Opioid Use
- Login or register to post comments
- Feed: Health of the Public
- Original article